Lv6
1640 积分 2025-04-25 加入
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
19小时前
待确认
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
19小时前
已完结
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
19小时前
已完结
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors
5天前
已完结
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
10天前
已完结
MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types
15天前
已完结
MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer
15天前
已完结
Unleashing the therapeutic potential of human kallikrein-related serine proteases
21天前
已完结
B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond
1个月前
已完结
Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
1个月前
已完结
皖公网安备34019202002308
